skip to Main Content

Dr. Mizrahi on Addition of PARP Inhibitors to Chemotherapy in Mutated Pancreatic Cancer

Dr. Mizrahi on Addition of PARP Inhibitors to Chemotherapy in Mutated Pancreatic Cancer
Jonathan Mizrahi, MD, fellow at The University of Texas MD Anderson Cancer Center, discusses the addition of veliparib to chemotherapy in BRCA1/2 or PALB2-mutated pancreatic cancer.

In a recent randomized phase 2 trial, investigators examined the combination of gemcitabine and cisplatin with or without the PARP inhibitor in the frontline treatment of patients with pancreatic ductal adenocarcinomas and a germline BRCA1/2 or PALB2 mutation, says Mizrahi.Investigators wanted to evaluate whether the addition of a PARP inhibitor to chemotherapy would improve the effectiveness of chemotherapy in this patient population. Watch here . . . 


Back To Top